ZNF235 Inhibitors
Chemical inhibitors of ZNF235 can act through various mechanisms to modulate the activity of this protein. Alsterpaullone, Purvalanol A, and Roscovitine are cyclin-dependent kinase inhibitors that can interrupt the cell cycle progression. By doing so, they can indirectly inhibit the functioning of ZNF235, which is likely dependent on the cell cycle's precise regulation for its role in DNA damage response and cell division. Similarly, SP600125, by inhibiting c-Jun N-terminal kinase, can impact the transcriptional regulation activities of ZNF235, as this kinase is part of stress signaling pathways that influence transcription factors. LY294002 and Wortmannin, both phosphoinositide 3-kinase inhibitors, can disrupt downstream processes that ZNF235 might influence, especially those related to transcriptional regulation associated with growth and survival pathways.
Moreover, Rapamycin, which targets the mTOR signaling pathway, can affect cell growth and proliferation signals that are crucial for ZNF235's function. PD98059 and U0126, selective inhibitors of the MAPK/ERK pathway, can disrupt the signaling necessary for ZNF235's transcription factor activity, particularly with regard to extracellular signals that utilize this pathway. SB203580 targets p38 MAP kinase and can inhibit ZNF235's role in gene regulation in response to stress signals mediated by this kinase. Lastly, Sorafenib and Sunitinib, which inhibit various tyrosine protein kinases and receptor tyrosine kinases respectively, can decrease the activity of ZNF235 by inhibiting signaling pathways that ZNF235 may be involved in, especially those related to cell signaling and regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone acts as a cyclin-dependent kinase inhibitor, which can lead to the inhibition of cell cycle progression. By interrupting the cell cycle, ZNF235, which has roles in cell division and DNA damage response, might be indirectly inhibited as its proper function is dependent on the precise timing and regulation of the cell cycle. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is another cyclin-dependent kinase inhibitor that can block cell cycle progression. Inhibition of these kinases can indirectly inhibit ZNF235 by disrupting the cellular environment it requires to function properly, particularly in roles connected to cell cycle checkpoints and DNA repair mechanisms. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits cyclin-dependent kinases. Through this inhibition, the activity of ZNF235 can be indirectly reduced since its function may be tied to the phosphorylation status of proteins involved in cell cycle control and transcriptional regulation, which are governed by these kinases. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is involved in stress signaling pathways that can affect transcription factors. As ZNF235 is a transcription factor, inhibition of JNK can lead to reduced transcriptional activation of certain genes, potentially including those that ZNF235 regulates, thus indirectly inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K signaling is involved in numerous cellular processes, including growth and survival. Inhibiting PI3K can disrupt processes downstream that ZNF235 might influence, particularly if ZNF235 plays a role in transcriptional regulation linked to these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor with a mechanism similar to LY294002. By inhibiting PI3K, it can indirectly inhibit ZNF235 by disrupting the signaling pathways necessary for its transcriptional regulatory functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. By inhibiting mTOR signaling, proteins downstream that are regulated by this pathway, and which may be critical for the function of ZNF235, can be indirectly inhibited, thus inhibiting the functional role of ZNF235 in cell growth and proliferation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of the MAPK/ERK pathway. Since the MAPK/ERK pathway is implicated in the regulation of a variety of cellular activities, including gene expression, PD98059 can indirectly inhibit ZNF235's function by impeding the signaling required for its transcriptional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also an inhibitor of the MAPK/ERK pathway. By inhibiting this pathway, U0126 can indirectly inhibit the function of ZNF235 by affecting the signaling required for the transcription factor activity of ZNF235, especially if ZNF235 is involved in the response to extracellular signals that are mediated through the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, which is involved in the response to stress and cytokines. If ZNF235 is involved in gene regulation in response to stress signals mediated by the p38 MAP kinase, then inhibition of this pathway by SB203580 can indirectly inhibit the function of ZNF235. | ||||||